PAMP
PTGX icon

Polar Asset Management Partners’s Protagonist Therapeutics PTGX Stock Holding History

Polar Asset Management Partners’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-31,400
Closed -$908K – 807
2024
Q1 		$908K Buy
+31,400
New +$854K 0.02% 446

Other funds holding PTGX

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JFG
Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Polar Asset Management Partners's PTGX Position: Q2 2024 in Review

Polar Asset Management Partners sold out of Protagonist Therapeutics (PTGX) in Q2 2024, closing a stake of 31,400 shares — an estimated $908K sold.

Polar Asset Management Partners first reported a position in PTGX in Q1 2024 and held it in 1 quarter. The position peaked at $908K in Q1 2024. 188 funds tracked by Wall St. Rank hold PTGX as of Q2 2024.

  • Polar Asset Management Partners reported no remaining Protagonist Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Polar Asset Management Partners sold 31,400 Protagonist Therapeutics shares in Q2 2024, an estimated $908K.
  • Polar Asset Management Partners first reported a position in Protagonist Therapeutics in Q1 2024 and held it in 1 quarter.
  • Polar Asset Management Partners's Protagonist Therapeutics position peaked at $908K in Q1 2024.
  • 188 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2024.

Based on Polar Asset Management Partners's 13F filing for Q2 2024, filed 14 Aug 2024.